Tests génomiques pour le traitement du cancer October 15, 2024 L’un des plus grands défis dans le traitement du cancer est que chaque cancer se comporte différemment. Nombreuses questions se posent telles que : Va-t-i... Continue Reading
EndoPredict: Now Available in Australia, Offering Personalized Breast Cancer Management October 11, 2024 We are excited to announce that the EndoPredict test, a leading prognostic tool for early-stage breast cancer, is now available in Australia with NATA accredit... Continue Reading
Genomische Testung September 20, 2024 Eine der größten Herausforderungen bei der Behandlung von Krebs ist, dass sich jeder Krebs anders verhalten kann. Wird er schnell oder langsam wachsen? Wird ... Continue Reading
Genomic testing for cancer treatment September 20, 2024 One of the biggest challenges in treating cancer is that each one can behave differently to the next. Will it grow fast, or slow? Will it spread to other organ... Continue Reading
New publication: Real-world study prospectively shows prognostic and predictive accuracy May 22, 2024 We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification an... Continue Reading
NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer May 13, 2024 New guidance from the National Institute for Health and Care Excellence (NICE)1 The National Institute for Health and Care Excellence (NICE) in the UK has i... Continue Reading
Phase III validation of EndoPredict® confirms prognostic power May 6, 2024 Prognostic value of EndoPredict® test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer scre... Continue Reading
Updated ESMO Guidelines 2024 February 26, 2024 Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinica... Continue Reading
EndoPredict® at SABCS – Prospective long-term and real-world data December 16, 2022 Two prospective real-world studies presented at SABCS show EndoPredict® accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th Decemb... Continue Reading
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium September 19, 2022 Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con... Continue Reading